Letter to the Editor: Contemporary Screening and Treatment of Hypertrophic Cardiomyopathy

摘要

Hypertrophic cardiomyopathy (HCM) is an autosomal dominant genetic heart disorder.1 HCM is characterized by left ventricular (LV) hypertrophy (LVH) without LV dilatation, particularly of the interventricular septum, in the absence of other predisposing conditions such as hypertension or valvular disease. Most affected individuals remain unidentified and asymptomatic.2 HCM is a relatively common genetic disease, with a 1 in 500 prevalence by echocardiogram in the general population.3Clinical screening with a 12-lead electrocardiogram (ECG) and transthoracic echocardiogram (TTE) is recommended for families of patients with HCM disease. The frequency of screening evaluations depends on the individual's age, symptoms, and the presence of other risk factors. Individuals with a family history of sudden cardiac death and/or athletes participating in intense training programs should be screened for HCM. Patients with a clinical suspicion of early LVH, especially in the presence of cardiac symptoms (ie, angina, shortness of breath, syncope, palpitations, or murmur), should also be screened for HCM.